Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Herpesviridae
Published in: Herpesviridae 1/2012

Open Access 01-12-2012 | Review

Herpes simplex virus and varicella zoster virus, the house guests who never leave

Authors: Paul R Kinchington, Anthony J St Leger, Jean-Marc G Guedon, Robert L Hendricks

Published in: Herpesviridae | Issue 1/2012

Login to get access

Abstract

Human alphaherpesviruses including herpes simplex viruses (HSV-1, HSV-2) and varicella zoster virus (VZV) establish persistent latent infection in sensory neurons for the life of the host. All three viruses have the potential to reactivate causing recurrent disease. Regardless of the homology between the different virus strains, the three viruses are characterized by varying pathologies. This review will highlight the differences in infection pattern, immune response, and pathogenesis associated with HSV-1 and VZV.
Appendix
Available only for authorised users
Literature
1.
Mitchell BM, Bloom DC, Cohrs RJ, Gilden DH, Kennedy PG: Herpes simplex virus-1 and varicella-zoster virus latency in ganglia. J Neurovirol. 2003, 9: 194-204.PubMed
2.
Rouse BT, Kaistha SD: A tale of 2 alpha-herpesviruses: lessons for vaccinologists. Clin Infect Dis. 2006, 42: 810-817. 10.1086/500141.PubMed
3.
Kaufer BB, Smejkal B, Osterrieder N: The varicella-zoster virus ORFS/L (ORF0) gene is required for efficient viral replication and contains an element involved in DNA cleavage. J Virol. 2010, 84: 11661-11669. 10.1128/JVI.00878-10.PubMedCentralPubMed
4.
Umbach JL, Nagel MA, Cohrs RJ, Gilden DH, Cullen BR: Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. J Virol. 2009, 83: 10677-10683. 10.1128/JVI.01185-09.PubMedCentralPubMed
5.
6.
DeLuca NA, McCarthy AM, Schaffer PA: Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985, 56: 558-570.PubMedCentralPubMed
7.
Sato B, Ito H, Hinchliffe S, Sommer MH, Zerboni L, Arvin AM: Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J Virol. 2003, 77: 5607-5620. 10.1128/JVI.77.10.5607-5620.2003.PubMedCentralPubMed
8.
Felser JM, Kinchington PR, Inchauspe G, Straus SE, Ostrove JM: Cell lines containing varicella-zoster virus open reading frame 62 and expressing the “IE” 175 protein complement ICP4 mutants of herpes simplex virus type 1. J Virol. 1988, 62: 2076-2082.PubMedCentralPubMed
9.
Tyler JK, Orr A, Everett RD: Replacement of the herpes simplex virus type 1 Vmw175 DNA binding domain with its varicella-zoster virus counterpart results in a protein with novel regulatory properties that can support virus growth. J Gen Virol. 1997, 78 (Pt 1): 179-188.PubMed
10.
Kinchington PR, Fite K, Seman A, Turse SE: Virion association of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, requires expression of the VZV open reading frame 66 protein kinase. J Virol. 2001, 75: 9106-9113. 10.1128/JVI.75.19.9106-9113.2001.PubMedCentralPubMed
11.
Sen N, Sommer M, Che X, White K, Ruyechan WT, Arvin AM: Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol. 2010, 84: 9240-9253. 10.1128/JVI.01147-10.PubMedCentralPubMed
12.
Perera LP, Kaushal S, Kinchington PR, Mosca JD, Hayward GS, Straus SE: Varicella-zoster virus open reading frame 4 encodes a transcriptional activator that is functionally distinct from that of herpes simplex virus homology ICP27. J Virol. 1994, 68: 2468-2477.PubMedCentralPubMed
13.
Kyratsous CA, Walters MS, Panagiotidis CA, Silverstein SJ: Complementation of a herpes simplex virus ICP0 null mutant by varicella-zoster virus ORF61p. J Virol. 2009, 83: 10637-10643. 10.1128/JVI.01144-09.PubMedCentralPubMed
14.
Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995, 375 (6530): 411-415. 10.1038/375411a0.PubMed
15.
Spear PG: Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004, 6: 401-410. 10.1111/j.1462-5822.2004.00389.x.PubMed
16.
Berarducci B, Rajamani J, Zerboni L, Che X, Sommer M, Arvin AM: Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci U S A. 2010, 107: 282-287. 10.1073/pnas.0912373107.PubMedCentralPubMed
17.
Li Q, Krogmann T, Ali MA, Tang WJ, Cohen JI: The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor. J Virol. 2007, 81: 8525-8532. 10.1128/JVI.00286-07.PubMedCentralPubMed
18.
Li Q, Ali MA, Cohen JI: Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell. 2006, 127: 305-316. 10.1016/j.cell.2006.08.046.PubMed
19.
Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM: Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells. J Virol. 2011, 85: 4095-4110. 10.1128/JVI.02596-10.PubMedCentralPubMed
20.
Arvin AM, Oliver S, Reichelt M, Moffat JF, Sommer M, Zerboni L, Berarducci B: Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis. Curr Top Microbiol Immunol. 2010, 342: 129-146. 10.1007/82_2009_1.PubMed
21.
Cohen JI, Seidel K: Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. J Virol. 1994, 68: 7850-7858.PubMedCentralPubMed
22.
Tischer BK, Kaufer BB, Sommer M, Wussow F, Arvin AM, Osterrieder N: A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol. 2007, 81: 13200-13208. 10.1128/JVI.01148-07.PubMedCentralPubMed
23.
Che X, Reichelt M, Sommer MH, Rajamani J, Zerboni L, Arvin AM: Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J Virol. 2008, 82: 5825-5834. 10.1128/JVI.00303-08.PubMedCentralPubMed
24.
Pasieka TJ, Lu B, Leib DA: Enhanced Pathogenesis of an Attenuated Herpes Simplex Virus for Mice Lacking Stat1. J Virol. 2008, 82: 6052-6055. 10.1128/JVI.00297-08.PubMedCentralPubMed
25.
Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW: Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses In Vivo. J Exp Med. 1999, 189: 663-672. 10.1084/jem.189.4.663.PubMedCentralPubMed
26.
Arvin AM, Moffat JF, Sommer M, Oliver S, Che X, Vleck S, Zerboni L, Ku CC: Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol. 2010, 342: 189-209. 10.1007/82_2010_29.PubMedCentralPubMed
27.
Ku CC, Besser J, Abendroth A, Grose C, Arvin AM: Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol. 2005, 79: 2651-2658. 10.1128/JVI.79.5.2651-2658.2005.PubMedCentralPubMed
28.
Huch JH, Cunningham AL, Arvin AM, Nasr N, Santegoets SJ, Slobedman E, Slobedman B, Abendroth A: Impact of varicella zoster virus on dendritic cell subsets in human skin during natural infection. J Virol. 2010, 84: 4060-4072. 10.1128/JVI.01450-09.PubMedCentralPubMed
29.
Morrow G, Slobedman B, Cunningham AL, Abendroth A: Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol. 2003, 77: 4950-4959. 10.1128/JVI.77.8.4950-4959.2003.PubMedCentralPubMed
30.
Abendroth A, Morrow G, Cunningham AL, Slobedman B: Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J Virol. 2001, 75: 6183-6192. 10.1128/JVI.75.13.6183-6192.2001.PubMedCentralPubMed
31.
Guo Y, Audry M, Ciancanelli M, Alsina L, Azevedo J, Herman M, Anguiano E, Sancho-Shimizu V, Lorenzo L, Pauwels E, et al: Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med. 2011, 208: 2083-2098. 10.1084/jem.20101568.PubMedCentralPubMed
32.
Ku C-C, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM: Varicella-Zoster Virus Transfer to Skin by T Cells and Modulation of Viral Replication by Epidermal Cell Interferon-α. J Exp Med. 2004, 200: 917-925. 10.1084/jem.20040634.PubMedCentralPubMed
33.
Arvin AM, Kushner JH, Feldman S, Baehner RL, Hammond D, Merigan TC: Human Leukocyte Interferon for the Treatment of Varicella in Children with Cancer. N Engl J Med. 1982, 306: 761-765. 10.1056/NEJM198204013061301.PubMed
34.
Baskin H, Ellermann-Eriksen S, Lovmand J, Mogensen SC: Herpes simplex virus type 2 synergizes with interferon-gamma in the induction of nitric oxide production in mouse macrophages through autocrine secretion of tumour necrosis factor-alpha. J Gen Virol. 1997, 78: 195-203.PubMed
35.
Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL: Macrophage Control of Herpes Simplex Virus Type 1 Replication in the Peripheral Nervous System. J Immunol. 1999, 162: 2895-2905.PubMed
36.
Reichelt M, Wang L, Sommer M, Perrino J, Nour AM, Sen N, Baiker A, Zerboni L, Arvin AM: Entrapment of Viral Capsids in Nuclear PML Cages Is an Intrinsic Antiviral Host Defense against Varicella-Zoster Virus. PLoS Pathog. 2011, 7: e1001266-10.1371/journal.ppat.1001266.PubMedCentralPubMed
37.
Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, Heath WR, Carbone FR: Epidermal Viral Immunity Induced by CD8{Abendroth, #49}+Dendritic Cells But Not by Langerhans Cells. Science. 2003, 301: 1925-1928. 10.1126/science.1087576.PubMed
38.
Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, Lew AM, Shortman K, Heath WR, Carbone FR: Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming. Immunity. 2006, 25: 153-162. 10.1016/j.immuni.2006.04.017.PubMed
39.
Jirmo AC, Nagel C-H, Bohnen C, Sodeik B, Behrens GMN: Contribution of Direct and Cross-Presentation to CTL Immunity against Herpes Simplex Virus 1. J Immunol. 2009, 182: 283-292.PubMed
40.
Smith CM, Belz GT, Wilson NS, Villadangos JA, Shortman K, Carbone FR, Heath WR: Cutting Edge: Conventional CD8α + Dendritic Cells Are Preferentially Involved in CTL Priming After Footpad Infection with Herpes Simplex Virus-1. J Immunol. 2003, 170: 4437-4440.PubMed
41.
Lee HK, Zamora M, Linehan MM, Iijima N, Gonzalez D, Haberman A, Iwasaki A: Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J Exp Med. 2009, 206: 359-370. 10.1084/jem.20080601.PubMedCentralPubMed
42.
Sprecher E, Becker Y: Langerhans cell density and activity in mouse skin and lymph nodes affect herpes simplex type 1 (HSV-1) pathogenicity. Arch Virol. 1989, 107: 191-205. 10.1007/BF01317916.PubMed
43.
Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG: Entry of Alphaherpesviruses Mediated by Poliovirus Receptor-Related Protein 1 and Poliovirus Receptor. Science. 1998, 280: 1618-1620. 10.1126/science.280.5369.1618.PubMed
44.
Montgomery RI, Warner MS, Lum BJ, Spear PG: Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family. Cell. 1996, 87: 427-436. 10.1016/S0092-8674(00)81363-X.PubMed
45.
Chiu YG, Bowers WJ, Lim ST, Ryan DA, Federoff HJ: Effects of Herpes Simplex Virus Amplicon Transduction on Murine Dendritic Cells. Hum Gene Ther. 2009, 20: 442-452. 10.1089/hum.2008.160.PubMedCentralPubMed
46.
Mikloska Z, Bosnjak L, Cunningham AL: Immature Monocyte-Derived Dendritic Cells Are Productively Infected with Herpes Simplex Virus Type 1. J Virol. 2001, 75: 5958-5964. 10.1128/JVI.75.13.5958-5964.2001.PubMedCentralPubMed
47.
Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G, Hauber J, Steinkasserer A: Mature Dendritic Cells Infected with Herpes Simplex Virus Type 1 Exhibit Inhibited T-Cell Stimulatory Capacity. J Virol. 2000, 74: 7127-7136. 10.1128/JVI.74.15.7127-7136.2000.PubMedCentralPubMed
48.
Morrow G, Slobedman B, Cunningham AL, Abendroth A: Varicella-Zoster Virus Productively Infects Mature Dendritic Cells and Alters Their Immune Function. J Virol. 2003, 77: 4950-4959. 10.1128/JVI.77.8.4950-4959.2003.PubMedCentralPubMed
49.
Rajasagi NK, Kassim SH, Kollias CM, Zhao X, Chervenak R, Jennings SR: CD4+ T Cells Are Required for the Priming of CD8+ T Cells following Infection with Herpes Simplex Virus Type 1. J Virol. 2009, 83: 5256-5268. 10.1128/JVI.01997-08.PubMedCentralPubMed
50.
Ashley R, Wald A, Corey L: Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection. J Virol. 1994, 68: 5284-5286.PubMedCentralPubMed
51.
Ashley R, Benedetti J, Corey L: Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol. 1985, 17: 153-166. 10.1002/jmv.1890170208.PubMed
52.
Russell MW, Mestecky J: Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 2002, 4: 667-677. 10.1016/S1286-4579(02)01585-X.PubMed
53.
Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL: Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis. 1982, 146: 260-265. 10.1093/infdis/146.2.260.PubMed
54.
Brunell PA, Gershon AA, Uduman SA, Steinberg S: Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster. J Infect Dis. 1975, 132: 49-54. 10.1093/infdis/132.1.49.PubMed
55.
Spruance SL, Evans TG, McKeough MB, Thai L, Araneo BA, Daynes RA, Mishkin EM, Abramovitz AS: Th1/Th2-like immunity and resistance to herpes simplex labialis. Antivir Res. 1995, 28: 39-55. 10.1016/0166-3542(95)00037-M.PubMed
56.
Koelle DM, Corey L: Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annu Rev Med. 2008, 59: 381-395. 10.1146/annurev.med.59.061606.095540.PubMed
57.
Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O, Strupp M, Arbusow V, Brandt T: Latent Herpesvirus Infection in Human Trigeminal Ganglia Causes Chronic Immune Response. Am J Pathol. 2003, 163: 2179-2184. 10.1016/S0002-9440(10)63575-4.PubMedCentralPubMed
58.
Verjans GMGM, Hintzen RQ, van Dun JM, Poot A, Milikan JC, Laman JD, Langerak AW, Kinchington PR, Osterhaus ADME: Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci. 2007, 104: 3496-3501. 10.1073/pnas.0610847104.PubMedCentralPubMed
59.
Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L: Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007, 204: 595-603. 10.1084/jem.20061792.PubMedCentralPubMed
60.
Verweij MC, Lipinska AD, Koppers-Lalic D, van Leeuwen WF, Cohen JI, Kinchington PR, Messaoudi I, Bienkowska-Szewczyk K, Ressing ME, Rijsewijk FAM, Wiertz EJHJ: The Capacity of UL49.5 Proteins To Inhibit TAP Is Widely Distributed among Members of the Genus Varicellovirus. J Virol. 2011, 85: 2351-2363. 10.1128/JVI.01621-10.PubMedCentralPubMed
61.
Eisfeld AJ, Yee MB, Erazo A, Abendroth A, Kinchington PR: Downregulation of Class I Major Histocompatibility Complex Surface Expression by Varicella-Zoster Virus Involves Open Reading Frame 66 Protein Kinase-Dependent and -Independent Mechanisms. J Virol. 2007, 81: 9034-9049. 10.1128/JVI.00711-07.PubMedCentralPubMed
62.
Abendroth A, Kinchington PR, Slobedman B: Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol. 2010, 342: 155-171. 10.1007/82_2010_41.PubMedCentralPubMed
63.
Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB: Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 1984, 309: 633-635. 10.1038/309633a0.PubMed
64.
Aubert M, O’Toole J, Blaho JA: Induction and Prevention of Apoptosis in Human HEp-2 Cells by Herpes Simplex Virus Type 1. J Virol. 1999, 73: 10359-10370.PubMedCentralPubMed
65.
Ambagala AP, Cohen JI: Varicella-Zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response. J Virol. 2007, 81: 7844-7851. 10.1128/JVI.00325-07.PubMedCentralPubMed
66.
Hood C, Cunningham AL, Slobedman B, Arvin AM, Sommer MH, Kinchington PR, Abendroth A: Varicella-Zoster Virus ORF63 Inhibits Apoptosis of Primary Human Neurons. J Virol. 2006, 80: 1025-1031. 10.1128/JVI.80.2.1025-1031.2006.PubMedCentralPubMed
67.
Sloan E, Henriquez R, Kinchington P, Slobedman B, Abendroth A: Varicella zoster virus inhibition of the NFκB pathway during infection of human dendritic cells: role for ORF61 as a modulator of NFκB activity. J Virol. 2011, 86: 1193-1202.PubMed
68.
Azarkh Y, Gilden D, Cohrs RJ: Molecular characterization of varicella zoster virus in latently infected human ganglia: physical state and abundance of VZV DNA, Quantitation of viral transcripts and detection of VZV-specific proteins. Curr Top Microbiol Immunol. 2010, 342: 229-241. 10.1007/82_2009_2.PubMedCentralPubMed
69.
Pevenstein SR, Williams RK, McChesney D, Mont EK, Smialek JE, Straus SE: Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol. 1999, 73: 10514-10518.PubMedCentralPubMed
70.
Gershon AA, Chen J, Gershon MD: A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons. J Infect Dis. 2008, 197 (Suppl 2): S61-S65.PubMed
71.
Gary L, Gilden DH, Cohrs RJ: Epigenetic regulation of varicella-zoster virus open reading frames 62 and 63 in latently infected human trigeminal ganglia. J Virol. 2006, 80: 4921-4926. 10.1128/JVI.80.10.4921-4926.2006.PubMedCentralPubMed
72.
Knipe DM, Howley PM, Griffin DE: Fields’ Virology. 2007, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2503-2577-2775-2807. 5
73.
Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR: MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature. 2008, 454: 780-783.PubMedCentralPubMed
74.
Perng G-C, Jones C, Ciacci-Zanella J, Stone M, Henderson G, Yukht A, Slanina SM, Hofman FM, Ghiasi H, Nesburn AB, Wechsler SL: Virus-Induced Neuronal Apoptosis Blocked by the Herpes Simplex Virus Latency-Associated Transcript. Science. 2000, 287: 1500-1503. 10.1126/science.287.5457.1500.PubMed
75.
Tang S, Patel A, Krause PR: Novel Less-Abundant Viral MicroRNAs Encoded by Herpes Simplex Virus 2 Latency-Associated Transcript and Their Roles in Regulating ICP34.5 and ICP0 mRNAs. J Virol. 2009, 83: 1433-1442. 10.1128/JVI.01723-08.PubMedCentralPubMed
76.
Margolis TP, Imai Y, Yang L, Vallas V, Krause PR: Herpes Simplex Virus Type 2 (HSV-2) Establishes Latent Infection in a Different Population of Ganglionic Neurons than HSV-1: Role of Latency-Associated Transcripts. J Virol. 2007, 81: 1872-1878. 10.1128/JVI.02110-06.PubMedCentralPubMed
77.
Kramer MF, Coen DM: Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol. 1995, 69: 1389-1399.PubMedCentralPubMed
78.
Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP: Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci. 2002, 99: 978-983. 10.1073/pnas.022301899.PubMedCentralPubMed
79.
Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL: Cd8+ T Cells Can Block Herpes Simplex Virus Type 1 (HSV-1) Reactivation from Latency in Sensory Neurons. J Exp Med. 2000, 191: 1459-1466. 10.1084/jem.191.9.1459.PubMedCentralPubMed
80.
Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL: Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003, 18: 593-603. 10.1016/S1074-7613(03)00112-2.PubMedCentralPubMed
81.
St. Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL: Defining the Herpes Simplex Virus-Specific CD8+ T Cell Repertoire in C57BL/6 Mice. J Immunol. 2011, 186: 3927-3933. 10.4049/jimmunol.1003735.PubMedCentralPubMed
82.
Sheridan BS, Cherpes TL, Urban J, Kalinski P, Hendricks RL: Reevaluating the CD8 T-Cell Response to Herpes Simplex Virus Type 1: Involvement of CD8 T Cells Reactive to Subdominant Epitopes. J Virol. 2009, 83: 2237-2245. 10.1128/JVI.01699-08.PubMedCentralPubMed
83.
Ramachandran S, Davoli KA, Yee MB, Hendricks RL, Kinchington PR: Delaying the Expression of Herpes Simplex Virus Type 1 Glycoprotein B (gB) to a True Late Gene Alters Neurovirulence and Inhibits the gB-CD8+ T-Cell Response in the Trigeminal Ganglion. J Virol. 2010, 84: 8811-8820. 10.1128/JVI.00496-10.PubMedCentralPubMed
84.
Zerboni L, Sobel RA, Ramachandran V, Rajamani J, Ruyechan W, Abendroth A, Arvin A: The expression of varicella-zoster virus immediate early regulatory protein IE63 in neurons of latently infected human sensory ganglia. J Virol. 2010, 84: 3421-3430. 10.1128/JVI.02416-09.PubMedCentralPubMed
85.
Gowrishankar K, Slobedman B, Cunningham AL, Miranda-Saksena M, Boadle RA, Abendroth A: Productive Varicella-Zoster Virus Infection of Cultured Intact Human Ganglia. J Virol. 2007, 81: 6752-6756. 10.1128/JVI.02793-06.PubMedCentralPubMed
86.
Markus A, Grigoryan S, Sloutskin A, Yee MB, Zhu H, Yang IH, Thakor NV, Sarid R, Kinchington PR, Goldstein RS: Varicella-Zoster Virus (VZV) Infection of Neurons Derived from Human Embryonic Stem Cells: Direct Demonstration of Axonal Infection, Transport of VZV, and Productive Neuronal Infection. J Virol. 2011, 85: 6220-6233. 10.1128/JVI.02396-10.PubMedCentralPubMed
87.
Wang K, Lau TY, Morales M, Mont EK, Straus SE: Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level. J Virol. 2005, 79: 14079-14087. 10.1128/JVI.79.22.14079-14087.2005.PubMedCentralPubMed
88.
Cohrs RJ, Barbour M, Gilden DH: Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol. 1996, 70: 2789-2796.PubMedCentralPubMed
89.
Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, Silverstein SJ: Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A. 1995, 92: 10980-10984. 10.1073/pnas.92.24.10980.PubMedCentralPubMed
90.
Cohen JI, Krogmann T, Bontems S, Sadzot-Delvaux C, Pesnicak L: Regions of the varicella-zoster virus open reading frame 63 latency-associated protein important for replication in vitro are also critical for efficient establishment of latency. J Virol. 2005, 79: 5069-5077. 10.1128/JVI.79.8.5069-5077.2005.PubMedCentralPubMed
91.
Cohen JI, Krogmann T, Pesnicak L, Ali MA: Absence or overexpression of the Varicella-Zoster Virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces VZV latency in a rodent model. J Virol. 2007, 81: 1586-1591. 10.1128/JVI.01220-06.PubMedCentralPubMed
92.
Cohen JI, Krogmann T, Ross JP, Pesnicak L, Prikhod’ko EA: Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency. J Virol. 2005, 79: 6969-6975. 10.1128/JVI.79.11.6969-6975.2005.PubMedCentralPubMed
93.
Cohrs RJ, Barbour MB, Mahalingam R, Wellish M, Gilden DH: Varicella-zoster virus (VZV) transcription during latency in human ganglia: prevalence of VZV gene 21 transcripts in latently infected human ganglia. J Virol. 1995, 69: 2674-2678.PubMedCentralPubMed
94.
Hoover SE, Cohrs RJ, Rangel ZG, Gilden DH, Munson P, Cohen JI: Downregulation of varicella-zoster virus (VZV) immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro and with latency. J Virol. 2006, 80: 3459-3468. 10.1128/JVI.80.7.3459-3468.2006.PubMedCentralPubMed
95.
Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ: Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A. 1998, 95: 7080-7085. 10.1073/pnas.95.12.7080.PubMedCentralPubMed
96.
Mahalingam R, Wellish M, Cohrs R, Debrus S, Piette J, Rentier B, Gilden DH: Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A. 1996, 93: 2122-2124. 10.1073/pnas.93.5.2122.PubMedCentralPubMed
97.
Sadzot-Delvaux C, Arvin AM, Rentier B: Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis. 1998, 178 (Suppl 1): S43-S47.PubMed
98.
Xia D, Srinivas S, Sato H, Pesnicak L, Straus SE, Cohen JI: Varicella-zoster virus open reading frame 21, which is expressed during latency, is essential for virus replication but dispensable for establishment of latency. J Virol. 2003, 77: 1211-1218. 10.1128/JVI.77.2.1211-1218.2003.PubMedCentralPubMed
99.
Cohrs RJ, Gilden DH: Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia. J Virol. 2007, 81: 2950-2956. 10.1128/JVI.02745-06.PubMedCentralPubMed
100.
Ambagala AP, Bosma T, Ali MA, Poustovoitov M, Chen JJ, Gershon MD, Adams PD, Cohen JI: Varicella-zoster virus immediate-early 63 protein interacts with human antisilencing function 1 protein and alters its ability to bind histones h3.1 and h3.3. J Virol. 2009, 83: 200-209. 10.1128/JVI.00645-08.PubMedCentralPubMed
101.
Di Valentin E, Bontems S, Habran L, Jolois O, Markine-Goriaynoff N, Vanderplasschen A, Sadzot-Delvaux C, Piette J: Varicella-zoster virus IE63 protein represses the basal transcription machinery by disorganizing the pre-initiation complex. Biol Chem. 2005, 386: 255-267.PubMed
102.
Walters MS, Kyratsous CA, Wan S, Silverstein S: Nuclear import of the varicella-zoster virus latency-associated protein ORF63 in primary neurons requires expression of the lytic protein ORF61 and occurs in a proteasome-dependent manner. J Virol. 2008, 82: 8673-8686. 10.1128/JVI.00685-08.PubMedCentralPubMed
103.
Stallings CL, Duigou GJ, Gershon AA, Gershon MD, Silverstein SJ: The cellular localization pattern of Varicella-Zoster virus ORF29p is influenced by proteasome-mediated degradation. J Virol. 2006, 80: 1497-1512. 10.1128/JVI.80.3.1497-1512.2006.PubMedCentralPubMed
104.
Stallings CL, Silverstein SJ: Posttranslational modification and cell type-specific degradation of varicella-zoster virus ORF29p. J Virol. 2006, 80: 10836-10846. 10.1128/JVI.00966-06.PubMedCentralPubMed
105.
Farnsworth A, Goldsmith K, Johnson DC: Herpes Simplex Virus Glycoproteins gD and gE/gI Serve Essential but Redundant Functions during Acquisition of the Virion Envelope in the Cytoplasm. J Virol. 2003, 77: 8481-8494. 10.1128/JVI.77.15.8481-8494.2003.PubMedCentralPubMed
106.
Johnson DC, Spear PG: Monensin inhibits the processing of herpes simplex virus glycoproteins, their transport to the cell surface, and the egress of virions from infected cells. J Virol. 1982, 43: 1102-1112.PubMedCentralPubMed
107.
Cohrs RJ, Mehta SK, Schmid DS, Gilden DH, Pierson DL: Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol. 2008, 80: 1116-1122. 10.1002/jmv.21173.PubMedCentralPubMed
108.
Gilden D, Cohrs RJ, Mahalingam R, Nagel MA: Neurological disease produced by varicella zoster virus reactivation without rash. Curr Top Microbiol Immunol. 2010, 342: 243-253. 10.1007/82_2009_3.PubMedCentralPubMed
109.
Freeman ML, Sheridan BS, Bonneau RH, Hendricks RL: Psychological Stress Compromises CD8+ T Cell Control of Latent Herpes Simplex Virus Type 1 Infections. J Immunol. 2007, 179: 322-328.PubMedCentralPubMed
110.
Cherpes TL, Busch JL, Sheridan BS, Harvey SAK, Hendricks RL: Medroxyprogesterone Acetate Inhibits CD8+ T Cell Viral-Specific Effector Function and Induces Herpes Simplex Virus Type 1 Reactivation. J Immunol. 2008, 181: 969-975.PubMedCentralPubMed
111.
Decman V, Kinchington PR, Harvey SAK, Hendricks RL: Gamma Interferon Can Block Herpes Simplex Virus Type 1 Reactivation from Latency, Even in the Presence of Late Gene Expression. J Virol. 2005, 79: 10339-10347. 10.1128/JVI.79.16.10339-10347.2005.PubMedCentralPubMed
112.
Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL: Noncytotoxic Lytic Granule-Mediated CD8+ T Cell Inhibition of HSV-1 Reactivation from Neuronal Latency. Science. 2008, 322: 268-271. 10.1126/science.1164164.PubMedCentralPubMed
113.
Jiang X, Chentoufi AA, Hsiang C, Carpenter D, Osorio N, BenMohamed L, Fraser NW, Jones C, Wechsler SL: The Herpes Simplex Virus Type 1 Latency-Associated Transcript Can Protect Neuron-Derived C1300 and Neuro2A Cells from Granzyme B-Induced Apoptosis and CD8 T-Cell Killing. J Virol. 2011, 85: 2325-2332. 10.1128/JVI.01791-10.PubMedCentralPubMed
114.
Himmelein S, St Leger A, Knickelbein J, Rowe A, Freeman M, Hendricks R: Circulating herpes simplex type 1 (HSV-1)-specific CD8+ T cells do not access HSV-1 latently infected trigeminal ganglia. Herpesviridae. 2011, 2: 5-10.1186/2042-4280-2-5.PubMedCentralPubMed
115.
Chapman RS, Cross KW, Fleming DM: The incidence of shingles and its implications for vaccination policy. Vaccine. 2003, 21: 2541-2547. 10.1016/S0264-410X(03)00034-3.PubMed
116.
Camarena V, Kobayashi M, Kim JY, Roehm P, Perez R, Gardner J, Wilson AC, Mohr I, Chao MV: Nature and Duration of Growth Factor Signaling through Receptor Tyrosine Kinases Regulates HSV-1 Latency in Neurons. Cell Host Microbe. 2010, 8: 320-330. 10.1016/j.chom.2010.09.007.PubMedCentralPubMed
117.
Whitlow ZW, Kristie TM: Recruitment of the Transcriptional Coactivator HCF-1 to Viral Immediate-Early Promoters during Initiation of Reactivation from Latency of Herpes Simplex Virus Type 1. J Virol. 2009, 83: 9591-9595. 10.1128/JVI.01115-09.PubMedCentralPubMed
118.
Roxas M: Herpes zoster and postherpetic neuralgia: diagnosis and therapeutic considerations. Altern Med Rev. 2006, 11: 102-113.PubMed
119.
Gowrishankar K, Steain M, Cunningham AL, Rodriguez M, Blumbergs P, Slobedman B, Abendroth A: Characterization of the Host Immune Response in Human Ganglia after Herpes Zoster. J Virol. 2010, 84: 8861-8870. 10.1128/JVI.01020-10.PubMedCentralPubMed
120.
Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, Kinchington PR, Dickenson AH, Pheby T, Rice AS: Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience. 2007, 144: 1495-1508. 10.1016/j.neuroscience.2006.11.029.PubMedCentralPubMed
121.
Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin WJ, Kinchington PR, Krah DL, Abbadie C, Fleetwood-Walker SM: Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain. 2005, 118: 97-111. 10.1016/j.pain.2005.08.003.PubMed
122.
Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN: Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature. 2011, 477: 216-219. 10.1038/nature10339.PubMed
123.
Zerboni L, Sobel RA, Lai M, Triglia R, Steain M, Abendroth A, Arvin A: Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group a determinants in sensory neurons. J Virol. 2012, 86 (1): 578-583. 10.1128/JVI.05950-11.PubMedCentralPubMed
124.
Ouwendijk WJ, Choe A, Nagel MA, Gilden D, Osterhaus AD, Cohrs RJ, Verjans GM: Restricted varicella-zoster virus transcription in human trigeminal Ganglia obtained soon after death. J Virol. 2012 Sept, 86 (81): 10203-10206.PubMedCentralPubMed
Metadata
Title
Herpes simplex virus and varicella zoster virus, the house guests who never leave
Authors
Paul R Kinchington
Anthony J St Leger
Jean-Marc G Guedon
Robert L Hendricks
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Herpesviridae / Issue 1/2012
Electronic ISSN: 2042-4280
DOI
https://doi.org/10.1186/2042-4280-3-5

Other articles of this Issue 1/2012

Herpesviridae 1/2012 Go to the issue

Research

The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS)

Research

HSV-1-induced chemokine expression via IFI16-dependent and IFI16-independent pathways in human monocyte-derived macrophages

Research

Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study

Research

Evaluation of the IMMULITE®2000 CMV IgM assay

Research

Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits